期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
sST2水平与冠心病预后的相关性分析 被引量:5
1
作者 王硕 齐云燕 +3 位作者 王普 王亚茹 张晓婵 李柳 《昆明医科大学学报》 CAS 2022年第1期112-117,共6页
目的探讨可溶性生长刺激表达基因2蛋白(s ST2)与冠心病预后的相关性。方法纳入需行冠脉造影术及必要时支架植入术患者400名,均行sST2检测,按检测结果分为低浓度组(<35μg/mL)、中浓度组(35μg/mL-70μg/mL)、高浓度组(>70μg/mL)... 目的探讨可溶性生长刺激表达基因2蛋白(s ST2)与冠心病预后的相关性。方法纳入需行冠脉造影术及必要时支架植入术患者400名,均行sST2检测,按检测结果分为低浓度组(<35μg/mL)、中浓度组(35μg/mL-70μg/mL)、高浓度组(>70μg/mL),并行冠脉SYNTAX II评分,随访所有PCI术后患者360 d内发生MACE事件(包括包括心脏死亡、心肌梗死、心力衰竭、心脏原因再次入院、靶血管再次血运重建)的情况。结果(1)高浓度组(>70μg/mL)患者冠脉SYNTAX II评分显著高于低浓度组(<35μg/mL)、中浓度组(35~0μg/mL)患者(P<0.05)。(2)高浓度组(>70μg/mL)患者患者术后360 d内发生的MACE事件显著高于低浓度组(<35μg/mL)、中浓度组(35~70μg/mL)患者(P<0.05)。结论(1)sST2水平与冠脉SYNTAX II评分显著相关。(2)sST2水平与冠心病患者PCI术后360 d内发生的MACE事件显著相关。 展开更多
关键词 sST2 冠脉syntax ii评分 PCI MACE
下载PDF
心肌缺血预适应在紫杉醇释放冠脉球囊导管扩张术中的应用 被引量:2
2
作者 王硕 孙爱 +3 位作者 张慧杰 尤杨 魏立业 李柳 《昆明医科大学学报》 CAS 2021年第12期89-94,共6页
目的评价心肌缺血预适应在紫杉醇释放冠脉球囊导管术中应用价值。方法纳入行紫杉醇释放冠脉球囊导管患者210名,随机分为3组,一组为对照组,术中依据手术常规行药物球囊扩张术;二组为半分钟预适应组,在药物球囊扩张前,间隔3 min 2次应用... 目的评价心肌缺血预适应在紫杉醇释放冠脉球囊导管术中应用价值。方法纳入行紫杉醇释放冠脉球囊导管患者210名,随机分为3组,一组为对照组,术中依据手术常规行药物球囊扩张术;二组为半分钟预适应组,在药物球囊扩张前,间隔3 min 2次应用非顺应性球囊扩张狭窄部位30 s;三组为1 min适应组,在药物球囊扩张前,间隔3 min 2次应用非顺应性球囊扩张狭窄部位60 s。所有患者行冠脉SYNTAX II评分,记录经皮腔内冠状动脉成形术(percutaneous transluminal coronary angioplasty,PTCA)术前及术后24 h肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白I(cTnI)数值,记录术中发生心绞痛、快速型心律失常、缓慢型心律失常的情况,并随访所有患者术后180 d内发生MACE事件(包括包括心脏死亡、心肌梗死、心力衰竭、心脏原因再次入院、靶血管再次血运重建)及临床症状改善的情况。结果(1)3组患者PTCA术前CK、CK-MB、cTnI,以及术中发生心绞痛、快速型心律失常、缓慢型心律失常的情况,差异无统计学意义(P>0.05),1 min适应组患者在PTCA术后24 h的CK、CK-MB、cTnI显著低于对照组及半分钟预适应组(P<0.05);(2)1 min适应组患者在PTCA术后180 d内MACE事件发生率及临床症状改善情况显著优于对照组及半分钟预适应组(P<0.05)。结论(1)心肌缺血预适应在紫杉醇释放冠脉球囊导管术中应用可减少心肌坏死;(2)心肌缺血预适应在紫杉醇释放冠脉球囊导管术中应用可改善PTCA术预后及临床症状。 展开更多
关键词 缺血预适应 紫杉醇释放冠脉球囊导管 药物涂层球囊 冠脉syntax ii评分 经皮腔内冠状动脉成形术 主要不良心血管事件
下载PDF
Predictive Ability of the SYNergy Between Percutaneous Coronary Intervention with TAXus and Cardiac Surgery Score Ⅱ for Long-term Mortality in Patients with Three-vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Treated 被引量:5
3
作者 Ji-Qiang He Xian-Peng Yu Cheng Peng Quan Li Ya-Wei Luo Yue-Chun Gao Xiao-Ling Zhang Chang-Yan Wu Hua Zhao Yu-Chen Zhang Jing-Hua Liu Shu-Zheng Lyu Fang Chen 《Chinese Medical Journal》 SCIE CAS CSCD 2015年第16期2176-2182,共7页
Background:The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery Score Ⅱ (SS-Ⅱ) can well predict 4-year mortality in patients with complex coronary artery disease (CAD),and guide... Background:The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery Score Ⅱ (SS-Ⅱ) can well predict 4-year mortality in patients with complex coronary artery disease (CAD),and guide decision-making between coronary artery bypass graft surgery and percutaneous coronary intervention (PCI).However,there is lack of data regarding the utility of the SS-Ⅱ in patients with three-vessel CAD undergoing PCI treated with second-generation drug-eluting stents (DES).The purpose of the present study was to evaluate the ability of the SS-Ⅱ to predict long-term mortality in patients with three-vessel CAD undergoing PCI with second-generation DES.Methods:Totally,573 consecutive patients with de novo three-vessel CAD who underwent PCI with second-generation DES were retrospectively studied.According to the tertiles of the SS-Ⅱ,the patients were divided into three groups:The lowest SS-Ⅱ tertile (SS-Ⅱ ≤20),intermediate SS-Ⅱ tertile (SS-Ⅱ of 21-31),and the highest SS-Ⅱ tertile (SS-Ⅱ ≥32).The survival curves of the different groups were estimated by the Kaplan-Meier method.Univariate and multivariate Cox proportional hazard regression analyses were performed to evaluate the relationship between the SS-Ⅱ and 5-year mortality.The performance of the SS-Ⅱ with respect to predicting the rate of mortality was studied by calculating the area under the receiver operator characteristic (ROC) curve.The predictive ability of the SS-Ⅱ for 5-year mortality was evaluated and compared with the SS alone.Results:The overall SS-Ⅱ was 27.6 ± 9.0.Among patients in the lowest,intermediate and the highest SS-Ⅱ tertiles,the 5-year rates of mortality were 1.6%,3.2%,and 8.6%,respectively (P =0.003);the cardiac mortality rates were 0.5%,1.9%,and 5.2%,respectively (P =0.014).By multivariable analysis,adjusting for the potential confounders,the SS-Ⅱ was an independent predictor of 5-year mortality (hazard ratio:2.45,95% confidence interval:1.38-4.36;P=0.002).The SS-Ⅱ demonstrated a higher predictive accuracy for 5-year mortality compared with the SS alone (the area under the ROC curve was 0.705 and 0.598,respectively).Conclusion:The SS-Ⅱ is an independent predictor of 5-year mortality in patients with three-vessel CAD undergoing PCI treated with second-generation DES,and demonstrates a superior predictive ability over the SS alone. 展开更多
关键词 Mortality Percutaneous Coronary Intervention Predictive Ability Second-generation Drug-eluting Stents syntax score ii Three-vessel Coronary Artery Disease
原文传递
替格瑞洛联合强化阿托伐他汀治疗NSTE-ACS
4
作者 陆子华 傅娟 《临床心电学杂志》 2023年第4期278-282,287,共6页
目的 探究替格瑞洛与强化阿托伐他汀联合用药治疗非ST段抬高型急性冠脉综合征(NSTE-ACS)的疗效及对血清γ-谷氨酰基转移酶(GGT)、冠状动脉病变SYNTAX-Ⅱ评分和血管内皮功能的影响。方法 选取九江学院附属医院心内科2019年6月至2021年3... 目的 探究替格瑞洛与强化阿托伐他汀联合用药治疗非ST段抬高型急性冠脉综合征(NSTE-ACS)的疗效及对血清γ-谷氨酰基转移酶(GGT)、冠状动脉病变SYNTAX-Ⅱ评分和血管内皮功能的影响。方法 选取九江学院附属医院心内科2019年6月至2021年3月收治的年龄30~85岁的NSTE-ACS患者100例,按照随机数字表法分为联用组(n=50,替格瑞洛与强化阿托伐他汀联合用药)和常规组(n=50,氯吡格雷与常规剂量阿托伐他汀联合用药)。比较两组治疗NSTE-ACS的整体有效率及治疗前后血清GGT指标、SYNTAX-Ⅱ评分、肱动脉静息状态内径、血管内皮依赖性舒张功能(FMD)、非依赖性血管内皮舒张功能(NMD)和峰值血流变化率的变化情况。结果 联用组治疗有效率(47/50,94.0%)高于常规组(42/50,84.0%),差异具有统计学意义(P<0.05);两组治疗1月血清GGT水平均比治疗前低,联用组治疗1月、治疗3月的血清GGT水平[(35.32±3.07)U/L、(29.70±5.15)U/L]明显低于常规组[(49.41±2.15)U/L、(33.69±4.13)U/L],差异具有统计学意义(P<0.05);两组治疗前SYNTAX-Ⅱ评分无统计学差异(P>0.05),两组治疗后SYNTAX-Ⅱ评分均降低,且联用组治疗3月[(19.37±3.21)分]低于常规组[(22.15±3.46)分],差异具有统计学意义(P<0.05);两组患者肱动脉静息状态内径和NMD在治疗前后不存在统计学差异(P>0.05),两组FMD和峰值血流变化率在联合用药治疗后都比治疗前有所上升,联用组治疗后FMD[(6.25±1.06)%]、峰值血流变化率[(52.76±5.14)%]上升幅度高于常规组FMD[(5.54±1.08)%、(47.26±3.51)%],差异具有统计学意义(P<0.05)。结论 对NSTE-ACS患者使用替格瑞洛联合强化阿托伐他汀的治疗效果比常规用药好,血管内皮功能明显改善,可以有效降低血清GGT水平及SYNTAX-Ⅱ评分且更能抑制冠状动脉病变。 展开更多
关键词 替格瑞洛 强化阿托伐他汀 非ST段抬高型急性冠脉综合征 血清γ-谷氨酰基转移酶 syntax-Ⅱ评分 血管内皮功能
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部